Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19.

J Neurol Neurosurg Psychiatry · 2021 · PMC7841496 · PMID 33109706

Europe PMC DOI

hedged sentence

0.1030

closest p · 2.1× alpha

0.1030

boldest claim

The sentences

did not reach statistical significancep=0.103not close (p > 0.1)

Time to progression in King’s clinical stage Patients in the placebo arm experienced shorter times to progression in King’s clinical stage as compared with patients in the edaravone arm ( figure 3 ); the difference did not reach statistical significance (log-rank test, p=0.103).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.